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THE use of tetrasodium 2-methyl-1:4-naphthohydroquinone diphosphate
(Synkavit) as an adjunct to radiotherapy in the treatment of some inoperable
malignancies in humans has developed from a laboratory study ofthis compound.
Sensitization of cultures of chick fibroblasts towards X-irradiation as measured
by mitotic inhibition and by production of chromosomal abnormalities (Mitchell
and Simon-Reuss, 1947) has been confirmed (Mitchell and Simon-Reuss, 1952(a),
1952(b); Mitchell, 1955; Mitchell, Simon-Reuss and King, 1958). McKelvie
(1959) has shown that the anti-mitotic action of X-rays on barley roots was
increased by pretreatment with solutions of Synkavit.
However, since the radiosensitizing action on animal tumours has been
disputed, a short review of the relevant reports follows. Mitchell's preliminary
tests (Mitchell, 1952) indicated that repeated, large, intramuscular injections of
Synkavit probably increased the number of permanent retrogressions of the
primary tumour in rats carrying the Walker 256 carcinoma, but that the rather
high number of spontaneous retrogressions (15 per cent) threw doubt upon the
results. But the point was made, and this laterproved to be vital, that fluorescence
studies after intravenous injection showed that the maximum accumulation of
the compound seemed to occur 30 minutes after injection. Fuller experiments
followed (Mitchell, 1953). Here the spontaneous retrogressions had been almost
eliminated by carrying the tumour as an ascites tumour before transplanting,
and a single intravenous injection of Synkavit alone and in conjunction with
1100 r X-ray was studied. Two conclusions from these experiments are important.
Firstly, the dose of X-ray alone was sufficient to produce 32/78 permanent retro-
gressions (40 per cent) and the radiosensitivity of this system was confirmed in
another recorded experiment (120/274 permanent retrogressions-44 per cent).
Secondly, the combination of 1100 r and intravenous Synkavit showed 52/77
permanent retrogressions (67-5 per cent), an obvious sensitization of this already
radiosensitive tumour. Results of a quantitatively similar nature were given
by Mitchell (1955) and fuller and more complete experiments on this aspect of
our work are in the press (Mitchell, Simon-Reuss and King, 1959).
The most recent review of this problem is given by Tarnowski, Bane, Conrad,
Nickson, Stock and Sugiura (1958). This includes an unsuccessful attempt to
repeat Mitchell's experiments with the Walker 256 carcinoma. However,
reference to their results (Table VIII, p. 245) shows that 1900 r gave an 8 week
regression rate of only 9.8 per cent compared with untreated controls of 6-7 per
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cent, and that 2300 r gave only a 20 per cent regression. It therefore follows that,
in spite of a genuine attempt to repeat Mitchell's experiments, the New York
group were in fact working with a much more radioresistant tumour. Failure to
confirm Mitchell's work is therefore not surprising. Furthermore, the references
quoted in this review showing findings at variance with Mitchell's are, in no case,
comparable. Gellhorn and Gagliano (1950) were testing the effect of Synkavit
alone without X-ray; Dittrich and Schmermund (1953) were using an Ehrlich
mouse ascites carcinoma. This tumour is known to be radioresistant since a dose
of 1250 r causes no increase in dead cells within 48 hours (Klein and Forssberg,
1954). Friedmann and Bailley (1950) used a single intramuscular injection of
Synkavit on Jensen rat sarcoma with comparatively small doses of X-ray
Jolles (1952) was studying whole body irradiation of rabbits and guinea-pigs.
Cohen and Cohen (1959) used subcutaneous injections of menadione (2-methyl-
1:4-naphthoquinone), the corresponding hydroquinone or the tetrasodium salt
of the hydroquinone diphosphate (Synkavit), against mammary mouse tumours
whose radiocurability at 4200 r was less than 1 per cent. Some comments on this
latter paper have already been given (Mitchell, 1959). The other negative results
reported by Tarnowski et al. (1958) were concerned with carcinoma 63 and sarcoma
180 in mice. Freedlander, Reich, Levitan and French (1958) tested Synkavit
as a radiosensitiser of neuroblastoma C-1300 in mice and although the results
show obvious sensitization, the compound was not classified as a sensitizer
because no tests of the compound alone were given. Negative results against the
already-mentioned radioresistant Ehrlich mouse ascites tumour were obtained.
It therefore appears to me, that although most reviews and reports would
lead the casual reader to believe that Mitchell's animal radiosensitization results
are not reproducible, this view cannot be substantiated.
The small but significant increase in useful life of patients suffering from
histologically proved inoperable carcinoma of the bronchus treated by combined
intravenous Synkavit and X-ray compared to X-ray and intramuscular Synkavit
(which gives no better result than X-ray only) has been proved by clinical trials
with random allocation of patients over the past six years (Mitchell, 1955:
Mitchell, Simon-Reuss and King, 1959).
I have therefore tried to determine the nature of some of the biochemical
processes affected by Synkavit in the hope that an explanation of its radiosenisi-
tizing action might follow. An interference with some stage in the biosynthesis of
the nucleic acids seemed likely since it was previously shown (Mitchell, 1952)
that the antimitotic effect of Synkavit could be altered, and in some cases be
completely eliminated, by equimolar amounts of some ribonucleosides and
ribonucleotides. The effect of Synkavit on the uptake of labelled formate and
glycine into the purines of the acid soluble fraction (ASF), the deoxyribonucleic
acid (DNA) and ribonucleic acid (RNA) of the Ehrlich carcinoma growing as ani
ascites tumour in mice was therefore studied, one of the advantages ofthis system
for this type of experiment being the absence of a variable necrotic area such as
is found in solid tumours.
METHODS AND MATERIALS
Mouse ascites tumour.-The Ehrlich carcinoma (hyperdiploid strain of Lettre)
was obtained by the kind co-operation of the Chester Beatty Institute in 194&
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and has been carried by routine transplantation (0.2 ml.) every 8th day into the
peritoneal cavity of our laboratory strain white mice. The experimental animals
were used on the 6th or 7th day after implantation depending on the size of the
tumour.
14Clabelledcompoundswereobtainedfromthe Radiochemical Centre, Amersham.
Most of the counting was done on infinitely thin samples in a Nuclear-Chicago
Automatic Windowless Counter operating in an atmosphere of methane in the
proportional region. Samples and backgrounds were recorded to a standard
error of 5 per cent or less and the specific activities were calculated from optical
density measurements on the solutions before they were dried off under a lamp.
The molar extinction coefficients were those used previously (Marrian, 1954).
Decreasing volumes were dried off and counted until the mean specific activity
varied by less than 5 per cent from the extremes.
Ultra-violet absorption measurements were made on a Unicam SP 500 Spectro-
photometer, sometimes adapted for use with micro cells.
Estimation of Small Amounts of Synkavit in Solution
Ceric sulphate solution was prepared by shaking 4 g. ceric sulphate with 50 ml.
water and 2.8 ml. concentrated sulphuric acid until solution was complete. 50 ml.
water was added and the whole clarified by repeated filtration. This solution
quantitatively and immediately oxidises Synkavit to 2-methyl-1:4-naphtho-
quinone (Yamagishi, 1954; Clark, Kirby and Todd, 1958), thereby rendering
the molecule soluble in organic solvents. Dilute bromine water has the same
action. 0.1 ml. Synkavit solution (optical density 1.44 at 290 m/u.) was added
to 10 ml. water and the whole extracted with 2 x 1 ml. pure cyclohexane. The
second extract had zero optical density at 250 m,u. (at whichwavelength 2-methyl-
1:4-naphthoquinone absorbs maximally). 0-1 ml. ceric sulphate solution and
1 ml. cyclohexane were now added and the whole well shaken. The organic
phase was seperated off and had an optical density of 0-412 at 250 m,u. Since the
molar extinctions of Synkavit at 290 m,t. is 5600 and of the quinone at 250 m/t.
is 19,000 this simple extraction represents a recovery of about 79 per cent.
Similar estimations are possible using bromine water as the oxidiser, but in this
case excess bromine must be removed by a stream ofair or nitrogen before extract-
ing with cyclohexane.
Biological experiments.-The experimental mice were divided randomly
into two groups. The "treated" mice were injected with 2 mg. Synkavit in
0-1 ml. saline and the "controls" with 0.1 ml. saline. Each mouse was injected
with 0.1 ml. of the solution of labelled formate or glycine containing 1 mg. of
the precursor and usually about 20 ,tc. The animals were sacrificed two hours
later by breaking their necks.
The acid soluble fraction.-The ascites fluid, at least 8-10 ml. in each batch,
was removed by a syringe into an ice cooled centrifuge tube containing a few
drops of 2 per cent oxalate solution. An equal volume of cold 0-6 N HC104
was added and the mixture homogenised in an ice-cooled container (M.S.E.
"Atomix "maximum speed for 1 minute). The homogenate and vessel washings
were spun at 2000 r.p.m. for 5 minutes (M.S.E. Major centrifuge using precooled
containers). The supernatant was filtered into an ice cooled Buchner flask through
a pad of Hyflo over a sintered disc which had been well washed with ice water
and then ice cold 0-6 N HC104. The tissue residue was suspended in 5-10 ml.
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cold perchloric acid and spun down, the supernatant being filtered as before.
This whole process was repeated. The filter pad was finally washed with about
5 ml. cold 0.6 N HC104. The volume of the acid soluble extract was measured
and the solution clarified if necessary by filtering through a paper. A portion
was diluted 1/5 with N/10 HC1 and the optical density at 260mju. (peak) measured.
The separation of the purines from this fraction was usually done by evaporation
and acid hydrolysis (Marshak and Vogel, 1951) but a method which gives cleaner
separation on paper is as follows. The extract was neutralised with aqueous
sodium hydroxide solution and 10 ml. 10 per cent silver nitrate added. The
precipitate was spun off and heated at 100° with 10 ml. N HC1 for 1 hour. The
filtered hydrolysate was freed from acid by repeated evaporation in vacuo and
addition of water, and the final residue dissolved in a little water and run on
paper (Whatman 3 mm.) in iso-propanol/HCl (Wyatt, 1951). 10 ml. (about 1/8
of the total) of the neutralised acid soluble fractions (both treated and controls)
was acidified with a few drops of concentrated sulphuric acid and gently homo-
genised with small volumes (1-4 ml.) of pure cyclohexane. The organic phase
was sucked off, clarified by spinning, and the optical density at 250 m/t. measured.
This extraction was repeated until the cyclohexane had zero optical density:
3 and 6 per cent of the ultraviolet absorbing material was extracted from the
control and treated solutions respectively under these conditions. Addition of
ceric sulphate solution (or bromine water) caused a further 0-4 and 0-6 per cent
to become organic soluble; thus, the injected Synkavit could not have accounted
for more than 0.6per cent ofthe optical density ofthe treated acid soluble fraction,
but it should be noted that the spectrum of this extracted material did not
resemble 2-methyl-1:4-naphthoquinone. Aliquots of the treated and control
ASF were diluted with N/10 HC1 and the optical density at 260 mj/t measured
before and after treatment with excess bromine water, the excess being removed
by aeration. The optical density of the treated ASF decreased from 7.10 to
4-90, 5.00 and that of the control from 7-15 to 5.68, 5.53 (duplicate estimations).
The tissue residue
The following manipulations were all carried out in the same weighed 6 in. B19
test tube to avoid losses. The tissue residue insoluble in cold dilute perchloric
acid, including the small amountfrom thetop ofthe Hyflo filterpad, was suspended
twice in water, enough aqueous sodium hydroxide solution being added to the
second suspension to bring the supernatant to neutrality. The insolubles were
washed twice with alcohol, once with ether and refiuxed for 1 hour with 20 mi.
methanol/chloroform (1:1). The solids were then washed with alcohol, ether and
dried in vacuo and the total weight noted. The dried solids were well mixed with
a glass rod to ensure homogeneity.
Separation ofRNA and DNA purines and counting of the samples was carried
out as previously described (Marrian, 1954; Marrian, Hughes and Werba, 1956).
Estimations of DNA were carried out in duplicate on 20-30 mg. samples of
the tissue residue as described by Burton (1956).
RESULTS AND DISCUSSION
The results of these experiments are given in Tables I, II and III as the ratio
between the specific activity of the purines in the Synkavit treated and in the
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control mice (Relative Specific Activity). The variability of the results neces-
sitated many repetitions and, indeed, the final figures are the means of 22 experi-
ments where formate was the precursor; the addition of 5 experiments where
glycine was used did not alter the figures appreciably. Occasionally, some of the
results were so widely different from the means that some error either in manipu-
lation or in the metabolic state ofeither the control or treated mice had occurred.
Such results were eliminated from the final calculations by Chauvenet's criterion
(Palmer, 1912, quoted and discussed by Calvin et al., 1949); the number of
results deleted and their value are given in the tables. The arithmetical means
and standard deviations are given, and themeans have been recalculated using
logarithmic values since biological experiments are frequently better so expressed.
In the present series however, there is no significant difference between the results
by either calculation, but the logarithmic calculations require fewer deletions
by Chauvenet's criterion. The results left little doubt that one effect ofthe injected
Synkavit was to inhibit the synthesis of RNA purines from low molecular weight
precursors without affecting the synthesis of either DNA purines or the acid
solublepurine nucleotides. This suggested that the mode ofaction was to interfere
with the polymerisation of the acid soluble nucleotides to RNA and it would
follow that an accumulation of acid soluble nucleotides should occur. This was
indeed shown to be the case by comparing the amount of acid soluble ultra-
violet absorbing material per unit amount of DNA in the corresponding dry
tissues residues in each case. The results of an experiment where 8 mice were
divided randomly and treated as before is given in Table IV. The increase shown
in Table IV in the amount of acid soluble nucleotides per unit amount of DNA
in the Synkavit treated mice compared to the controls is not only in agreement
with the postulated block between the acid soluble fraction and the RNA but
the extent ofthe increase (23 per cent) is in very close agreement with the amount
by which the activity of the treated RNA purines have fallen below the control
RNA purines in the amount of precursor utilised (24 and 20 per cent for adenine
and guanine respectively).
TABLE I.-Acid Soluble Purines-Relative Specific Activities (R.S.A.)
22 Experiments with Formate as Precursor
R.S.A.
Number of Observations ,- -
observations deleted Arithmetical Logarithmic
Adenine . . 22 . Ar. 034 . 101±+006 0977 f 06
Lg. 0'34 . -004
Guanine . . 18 . Ar. 1.75, 1 94, 6-30 . 1-09+0-07 112 -11
Lg. 6.30 -0'11
22 Experiments with FormaZe and 5 with Glycine as Precursor
R.S.A.
Number of Observations ----
---
observations deleted Arithmetical Logarithmic
Adenine . . 27 . Ar. 034, 0-29 . 099±005 0.95i0'05
Lg. 0 34, 0-29
Guanine . . 22 . Ar. 1.75, 1.94, 6.30 . 1-05±007 07 0 07
Lg. 6.30 -0- 07
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TABLE II.-Deoxyribonucleic Acid Purines-Relative Specific Activities (R.S.A.)
22 Experiments with Formate as Precursor
R.S.A.
Number of Observations ,
observations deleted Arithmetical Logarithmic
Adenine . . 21 . Ar. 3-6, 1-64, 2 52, 1-91 . 0-90+0-06 098{+±
Lg. 3'6
Guanine . 21 None 1l00i0-06 1-~~00.-6 095(
+0-05
--007
22 Experiments with Formate and 5 with Glycine as Precursor
Number of
observations
Observations
deleted
24 . Ar. 3-6, 1-64, 2-52, 1.91
Lg. 3-6
24 None
R.S.A.
Arithmetical Logarithmic
0-87±0-05 0-93 0
0*98+006 {-0 07
~~~0.9±-6 094(
+0.05
-0-006
TABLE III.-Ribonucleic Acid Purines-Relative Specific Activities (R.S.A.)
22 Experiments with Formate as Precursor
R.S.A.
Observations -· -A
deleted Arithmetical Logarithmic
Ar. 5-0, 18, 63, 1.8 . 0740 07 074{+009
Lg. 5.0, 6'3
0-81±0-06 0-83+0-07
22 Experiments with Formate and 5 with Glycine as percursor
Observations
deleted
Ar. 5-0, 1-8, 6-3, 1.8
Lg. 5.0, 6-3
Ar. 1-43, 1-78
Lg. 1-78, 0-19
R.S.A.
Arithmetical Logarithmic
0.76+0-06 0.76+0-07
0-80+0-06 0-78i0-06
TABLE IV.-Accumulation of Acid Soluble Nucleotides after Synkavit Treatment.
Treated
Volume of ascites fluid . . . . . 20 ml.
Total ASF by O.D. at 260 myu. . . 596 units
Total DNA in the tissue residues by O.D. at 600 my. 250, 252 units
(Duplicate estimation)
Ratio DNA/ASF . . . . . . . 238
Ratios from 3 earlier experiments . . . . 2-0
1-8
2.1
Mean 2-1±0.1
Controls
25 ml.
604 units
296, 292 units
2-06
1 6
1-7
1*5
1-7i0-1
It was, of course, necessary to show that the increase in acid soluble ultra-
violet absorbing material was not due merely to the presence of the injected
Synkavit or some water soluble derivative. However, ceric sulphate or bromine
water estimations for the presence of Synkavit showed that the amount of Syn-
Adenine .
Guanine .
Adenine.
Guanine .
Number of
observations
20
20 Ar. 1-43, 1-78
Lg. 1-78
Adenine .
Guanine .
Number of
observations
25
25
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kavit which could have been present was insignificantly small. The action of
dilute bromine water on mixed purine and pyrimidine derivatives is to make the
latter transparent to ultraviolet light, thus allowing a crude differential analysis.
The ratio of pyrimidine to purines thus found in the control ASF was 0.28, while
that in the treated was 0.44 suggesting that the increase in the nucleotides was
not uniform. the pyrimidine inucleotides increasing in concentration relatively
more than the purines.
The action of Synkavit as a radiosensitizer may therefore involve interference
with RNA synthesis, while the X-ray is interfering with DNA synthesis, and this
two-pronged attack on the cell's functions may account for the more than additive
effect of combined treatments.
Some avenues for future work are suggested by these results. It will be interest-
ing to see whether Synkavit will inhibit polynucleotide phosphorylase, the enzyme
which Grunberg-Monago, Ortiz and Ochoa (1955) have shown to polymerise
ribonucleoside diphosphates to RNA like material. Furthermore, if it is the two
sided approach of combination therapy which is involved, then Synkavit may
increase the desired effects of therapy by alkylating agents allowing, perhaps,
remissions of acute leukaemia with less toxic side effects. And Actinomycin D,
which appears to sensitize human skin to irradiation (Kingsley-Pillers-personal
observations) may show this effect through an interference with RNA synthesis.
SUMMARY
The effect of tetrasodiumt 2-methyl-1:4-naphthohydroquinone diphosphate
(Synkavit) on the uptake of labelled formate or glycine into the purines of mouse
ascites tumnour has been studied over a 2-hour period. The compound does not
alter the uptake of the precursor into the purines of the acid soluble nucleotides
or of the deoxyribonucleic acid, but the uptake into the ribonucleic acid purines
is reduced by 20-25 per cent compared to the controls. This inhibition is accom-
painied by an increase in 23 per cent of the total ultraviolet absorption of the
acid soluble fraction which could not be accounted for by the presence of the
injected compound in this fraction. The pyrimidines in this fraction increased
in concentration relative to the purines.
The implications of these observations are discussed.
I gratefully record my thanks to Mrs. J. E. Hart and Miss J. Haird who
assisted in these experiments, and to Mrs. I. Simon-Reuss and Mr. E. A. King
who supplied me with the mice carrying the ascites tumour. The Synkavit used
in these and many other experiments was generously given by Roche Products
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